Close Menu

NEW YORK – Illumina said yesterday that it has partnered with Chinese molecular diagnostics firm AnchorDx to develop clinical oncology tests for the Chinese market.

Under the terms of the strategic collaboration, AnchorDx, based in Guangzhou in southern China, will use Illumina's MiSeqDx sequencing system to develop in vitro diagnostic cancer test kits and data analysis software. AnchorDx plans to develop genomic cancer tests that range from screening to diagnostic testing to treatment monitoring.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Dec
10
Sponsored by
Congenica II

This webinar will discuss the use of next-generation sequencing and an optimized variant interpretation workflow to increase diagnostic yield in complex clinical cases.